Exhibit 99.1
Advanced BioPhotonics Inc. and The Dartmouth Xxxxxxxxx Medical Center
Enter Into Pilot Site Research Agreement
BOHEMIA, N.Y.--(BUSINESS WIRE)--June 15, 2006--Advanced
BioPhotonics Inc. (OTCBB: ABPH):
-- Dartmouth Xxxxxxxxx Medical Center to Serve as a Pilot
Research Site to Investigate the Unique Use of Company's
DIRI(R) Technology in Identifying Perforator Vessels in
Plastic and Reconstructive Surgery Procedures
Advanced BioPhotonics Inc. (OTCBB: ABPH) a developer of next
generation medical imaging applications using advanced infrared
technology announced today that it has entered into an agreement with
The Dartmouth-Xxxxxxxxx Medical Center and Dartmouth Medical School
Department of Surgery. Dartmouth will participate in the company's
multi-center clinical trial investigating the use of Advanced
BioPhotonics' proprietary DIRI(R) method of dynamic infrared imaging
in mapping vascular perforator blood vessels in Plastic and
Reconstructive Surgery procedures.
"Dartmouth is the third luminary medical center in the United
States to join this multi-center trial. The company believes that
perforator vessel localization in Plastic and Reconstructive surgery
flap procedures represents an important surgical application that has
the potential to shorten O.R. procedure times by providing surgeons
with anatomical information and measurements not readily available
today with conventional imaging techniques" said Xxxxxx Xxxxx, Senior
Vice President of Advanced BioPhotonics. "We are delighted and
privileged to be working with Dartmouth's Department of Surgery on
this application."
To conduct this study, which is scheduled to begin within two
weeks, Dartmouth will utilize the Company's patented BioScanIR(R)
System, a functional medical imaging modality that provides a fast,
non-invasive, radiation-free method for detecting diseases that affect
perfusion and reperfusion in human tissue. The agreement is for a
period of one year.
The company expects at least one additional luminary medical
center to join this trial in the next several weeks and expects to
conclude the trial in September 2006.
"It will be very interesting to investigate the effectiveness of
this technology. We hope that it offers us a more effective way to
deal with some of our reconstructive challenges" said Xxxxxxxxxxx
Xxxxx, M.D., Plastic and Reconstructive Surgeon at the Dartmouth
Xxxxxxxxx Medical Center.
About Advanced BioPhotonics
Advanced BioPhotonics Inc. (OTCBB: ABPH) headquartered in Bohemia,
New York, is an innovative developer of medical imaging applications
using advanced infrared technology. Advanced BioPhotonics provides
imaging technology for clinicians and researchers for use in the
detection and management of diseases affecting perfusion or
reperfusion of tissue or organs.
Advanced BioPhotonics's mission is to improve the quality and
cost-effectiveness of healthcare services and research through
identifying, acquiring and adapting high-resolution infrared
technology for biomedical applications. For more information about the
Company and its technology, please visit xxxx://xxx.xxxxxxxxxx.xxx/.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could cause
actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such differences
include, but are not limited to, continued acceptance of the Company's
products and services in the marketplace, the ability of the Company
to develop effective new products and receive governmental approvals
of such products, competitive factors, dependence upon third-party
vendors, and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release.
CONTACT: Advanced BioPhotonics Inc.
Xxxxx X'Xxxxxx, 000-000-0000
xxxxxxxx@xxxxxxxxxx.xxx
or
Xxxxxx X. Xxxxx, 000-000-0000
xxxxxx@xxxxxxxxxx.xxx
or
Investors:
The Investor Relations Group
Xxxxx Xxxxx or Xxx Xxxxx, 212-825-3210
